PDF(Pubmed)
Abstract：
OBJECTIVE: This comparative analysis aimed to investigate the efficacy of Sivelestat Sodium Hydrate (SSH) combined with Ulinastatin (UTI) in the treatment of sepsis with acute respiratory distress syndrome (ARDS).
METHODS: A control group and an observation group were formed with eighty-four cases of patients with sepsis with ARDS, with 42 cases in each group. The control group was intravenously injected with UTI based on conventional treatment, and the observation group was injected with SSH based on the control group. Both groups were treated continuously for 7 days, and the treatment outcomes and efficacy of both groups were observed. The Murray Lung Injury Score (MLIS), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) were compared. Changes in respiratory function, inflammatory factors, and oxidative stress indicators were assessed. The occurrence of adverse drug reactions was recorded.
RESULTS: The total effective rate in the observation group (95.24%) was higher than that in the control group (80.95%) (P < 0.05). The mechanical ventilation time, intensive care unit (ICU) hospitalization time, and duration of antimicrobial medication in the observation group were shorter and multiple organ dysfunction syndrome incidence was lower than those in the control group (P < 0.05). The mortality rate of patients in the observation group (35.71%) was lower than that in the control group (52.38%), but there was no statistically significant difference between the two groups (P > 0.05). MLIS, SOFA, and APACHE II scores in the observation group were lower than the control group (P < 0.05). After treatment, respiratory function, inflammation, and oxidative stress were improved in the observation group (P < 0.05). Adverse reactions were not significantly different between the two groups (P > 0.05).
CONCLUSIONS: The combination of SSH plus UTI improves lung injury and pulmonary ventilation function, and reduces inflammation and oxidative stress in patients with sepsis and ARDS.
METHODS: A control group and an observation group were formed with eighty-four cases of patients with sepsis with ARDS, with 42 cases in each group. The control group was intravenously injected with UTI based on conventional treatment, and the observation group was injected with SSH based on the control group. Both groups were treated continuously for 7 days, and the treatment outcomes and efficacy of both groups were observed. The Murray Lung Injury Score (MLIS), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) were compared. Changes in respiratory function, inflammatory factors, and oxidative stress indicators were assessed. The occurrence of adverse drug reactions was recorded.
RESULTS: The total effective rate in the observation group (95.24%) was higher than that in the control group (80.95%) (P < 0.05). The mechanical ventilation time, intensive care unit (ICU) hospitalization time, and duration of antimicrobial medication in the observation group were shorter and multiple organ dysfunction syndrome incidence was lower than those in the control group (P < 0.05). The mortality rate of patients in the observation group (35.71%) was lower than that in the control group (52.38%), but there was no statistically significant difference between the two groups (P > 0.05). MLIS, SOFA, and APACHE II scores in the observation group were lower than the control group (P < 0.05). After treatment, respiratory function, inflammation, and oxidative stress were improved in the observation group (P < 0.05). Adverse reactions were not significantly different between the two groups (P > 0.05).
CONCLUSIONS: The combination of SSH plus UTI improves lung injury and pulmonary ventilation function, and reduces inflammation and oxidative stress in patients with sepsis and ARDS.
摘要：
目的：本对比分析旨在探讨盐酸西维来司钠（SSH）联合乌司他丁（UTI）治疗脓毒症合并急性呼吸窘迫综合征（ARDS）的疗效。
方法：84例脓毒症合并ARDS患者为对照组和观察组。每组42例。对照组在常规治疗基础上静脉注射UTI,观察组在对照组的基础上注射SSH。两组均连续治疗7天,观察两组的治疗效果和疗效。Murray肺损伤评分（MLIS），序贯器官衰竭评估(SOFA)比较了急性生理学和慢性健康评估II（APACHEII）。呼吸功能的变化，炎症因子，并对氧化应激指标进行评估。记录药物不良反应发生情况。
结果：观察组总有效率(95.24%)高于对照组(80.95%)(P<0.05)。机械通气时间,重症监护病房(ICU)住院时间,观察组抗菌药物使用时间短于对照组,多器官功能障碍综合征发生率低于对照组(P<0.05)。观察组患者死亡率(35.71%)低于对照组(52.38%),但两组间差异无统计学意义(P>0.05)。MLIS,SOFA,观察组患者的APACHEⅡ评分低于对照组(P<0.05)。治疗后,呼吸功能,炎症,观察组患者的氧化应激水平均有改善(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。
结论：SSH加UTI的组合可改善肺损伤和肺通气功能，减少脓毒症和ARDS患者的炎症和氧化应激。
方法：84例脓毒症合并ARDS患者为对照组和观察组。每组42例。对照组在常规治疗基础上静脉注射UTI,观察组在对照组的基础上注射SSH。两组均连续治疗7天,观察两组的治疗效果和疗效。Murray肺损伤评分（MLIS），序贯器官衰竭评估(SOFA)比较了急性生理学和慢性健康评估II（APACHEII）。呼吸功能的变化，炎症因子，并对氧化应激指标进行评估。记录药物不良反应发生情况。
结果：观察组总有效率(95.24%)高于对照组(80.95%)(P<0.05)。机械通气时间,重症监护病房(ICU)住院时间,观察组抗菌药物使用时间短于对照组,多器官功能障碍综合征发生率低于对照组(P<0.05)。观察组患者死亡率(35.71%)低于对照组(52.38%),但两组间差异无统计学意义(P>0.05)。MLIS,SOFA,观察组患者的APACHEⅡ评分低于对照组(P<0.05)。治疗后,呼吸功能,炎症,观察组患者的氧化应激水平均有改善(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。
结论：SSH加UTI的组合可改善肺损伤和肺通气功能，减少脓毒症和ARDS患者的炎症和氧化应激。
